Myosin Therapeutics selected for NCI 2026–2027 Investor Initiatives Showcase

Sep 16, 2026 18:00 (38d ago)

Verifying

Myosin Therapeutics joined the NCI’s 2026–2027 Investor Initiatives Showcase cohort.
30 companies were selected from NCI’s funded portfolio after review by over 70 investors and partners.
MT-125 is in the NCI-supported Phase 1/2 STAR-GBM clinical trial.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.